177Lu-PSMA-617
19/195
Phase 2 small_molecule active
Quick answer
177Lu-PSMA-617 for Metastatic Hormone Naive Prostate Cancer is a Phase 2 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Metastatic Hormone Naive Prostate Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active